Adverse event profile of five anti head and neck squamous cell carcinoma drugs: a descriptive analysis from WHO-VigiAccess
This comparative pharmacovigilance study highlights the diverse safety profiles of the five anti-HNSCC drugs. Clinicians should consider these ADRs when treating patients, especially elderly individuals or those with comorbidities. Personalized monitoring strategies should be developed to minimize risks and optimize therapeutic outcomes for HNSCC patients.
Authors
- Zhigang Xia (ORCID: https://orcid.org/0000-0001-9017-0553)
- Weimin Gao (ORCID: https://orcid.org/0000-0002-6758-9775)
- Tingfeng Zhou
- Yan Dong (ORCID: https://orcid.org/0000-0003-4448-2681)
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Jiaxing University (CN)
- First Hospital of Jiaxing (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-06-24
- DOI
- https://doi.org/10.3389/fphar.2025.1602276
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05